TacticScaleWhat Hualan Biological Vaccine (华兰疫苗) Does & How It Makes Money (301207.SZ)
Updated October 2026 · reflects Hualan Biological Vaccine's latest reported financials
Chinese vaccine maker focused on flu, rabies, and meningitis shots. It earns revenue by manufacturing its own vaccines and selling them in China, mainly flu vaccines, alongside other preventive vaccines.
How Hualan Biological Vaccine makes money
It earns revenue by manufacturing its own vaccines and selling them in China, mainly flu vaccines, alongside other preventive vaccines.
What Hualan Biological Vaccine does
Hualan Biological Vaccine is a Chinese biotech company founded in 2005 and based in Xinxiang. It researches, produces, and sells vaccines and genetically engineered biological products in China. Its main business is influenza vaccines: standard split-virus, quadrivalent, pediatric quadrivalent, and H1N1 formulations. It also sells meningococcal polysaccharide vaccines (ACYW135 and group A/C), a recombinant hepatitis B vaccine, a Vero-cell rabies vaccine, and an adsorbed tetanus vaccine. Its development pipeline includes a group A/C meningococcal conjugate vaccine, a DTaP combination vaccine, an Hib conjugate vaccine, a recombinant zoster vaccine made in CHO cells, mRNA influenza vaccines, and new adjuvanted flu vaccines. The company sells products it makes itself.
Products & services
- Quadrivalent influenza virus split vaccine
- Quadrivalent influenza split vaccine (pediatric)
- Influenza virus split vaccine
- ACYW135 meningococcal polysaccharide vaccine
- Freeze-dried human rabies vaccine (Vero cells)
- Recombinant hepatitis B vaccine (Hansenula polymorpha)
华兰疫苗是做什么的？
华兰生物疫苗股份有限公司成立于2005年，总部位于河南新乡，在中国从事疫苗和基因工程生物制品的研发、生产和销售。公司以流感疫苗为主，产品包括流感病毒裂解疫苗、四价流感疫苗（含儿童剂型）和甲型H1N1流感疫苗。它还生产ACYW135群和A群C群脑膜炎球菌多糖疫苗、重组乙肝疫苗（汉逊酵母）、冻干人用狂犬病疫苗（Vero细胞）和吸附破伤风疫苗。 在研产品包括A群C群脑膜炎球菌结合疫苗、无细胞百白破联合疫苗、b型流感嗜血杆菌结合疫苗、重组带状疱疹疫苗（CHO细胞）、mRNA流感疫苗和新型佐剂流感疫苗。公司销售自产产品。
What is Hualan Biological Vaccine worth?
On an owner-earnings DCF, Hualan Biological Vaccine's most-likely value is about ¥9 versus a recent price near ¥20 (110% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥4) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Hualan Biological Engineering (002007.SZ) · Chengdu Kanghua Biological Products (300841.SZ) · Walvax Biotechnology (300142.SZ) · Shenzhen Kangtai Biological Products (300601.SZ) · Chongqing Zhifei Biological Products (300122.SZ)